导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 15.24% | 258/1050 |
| 近一周 | 2.16% | 145/1104 |
| 近一月 | -1.72% | 111/1103 |
| 近一季 | -8.62% | 577/1094 |
| 近半年 | 9.68% | 283/1074 |
| 近一年 | 20.29% | 230/1020 |
| 近两年 | 171.59% | 85/926 |
| 近三年 | 132.97% | 68/834 |
| 成立以来 | 335.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.73% 615/1070 |
33.03% 298/1101 |
- - |
- - |
| 2025 | 69.91% 63/1065 |
8.53% 197/1014 |
0.93% 618/1038 |
52.09% 75/1050 |
1.98% 310/1065 |
| 2024 | 29.23% 23/1011 |
-6.17% 626/960 |
-2.99% 504/983 |
24.09% 26/991 |
14.40% 33/1011 |
| 2023 | -16.36% 576/952 |
3.27% 422/880 |
-7.02% 644/895 |
-7.60% 476/915 |
-5.74% 582/952 |
| 2022 | -19.50% 307/867 |
-22.17% 646/773 |
20.32% 19/806 |
-12.40% 422/845 |
-1.87% 530/867 |
| 2021 | 35.58% 48/740 |
-1.54% 205/580 |
25.99% 74/659 |
4.23% 139/704 |
4.86% 233/740 |
| 2020 | 42.44% 287/554 |
-9.06% 370/419 |
16.57% 329/466 |
8.55% 287/517 |
23.79% 82/554 |
| 2019 | 39.95% 221/410 |
25.01% 704/1149 |
-6.21% 792/1231 |
8.95% 131/390 |
9.56% 172/410 |
| 2018 | - - |
- - |
- - |
- - |
0.67% 3/1080 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 招商前沿医疗保健股票C | 0.8165 | 61.04% |
| 招商前沿医疗保健股票A | 0.8511 | 59.95% |
| 招商医药健康产业股票 | 2.6450 | 53.78% |
| 前海开源公共卫生股票A | 0.4748 | 42.37% |
| 嘉实医疗保健股票 | 2.6190 | 42.34% |
| 前海开源公共卫生股票C | 0.4647 | 42.24% |
| 广发医药精选股票A | 1.3315 | 41.03% |
| 广发医药精选股票C | 1.3103 | 40.86% |
| 交银医药创新股票C | 3.0948 | 37.26% |
| 交银医药创新股票A | 2.9144 | 36.05% |
| 西部利得事件驱动股票 VS. 东吴新产业精选股票A(580008) |